

June 26, 2015

## Announcements

### Smilow Cancer Hospital and Saint Francis Care Launch New Partnership

I am pleased to announce that after months of careful planning, our new partnership with Saint Francis brings the clinical program of Smilow Cancer Hospital at Yale-New Haven to the Saint Francis Campus. This partnership gives Saint Francis patients enhanced access to our clinical trials, broader screening and diagnostic tools, more treatment options, expanded psychosocial support, and enhanced pain management therapies. Saint Francis is known for exceptional patient and family centered cancer care. Smilow at Saint Francis will define the very best in cancer care, incorporating cancer genetics and personalized precision medicine to bring more cures to more patients in the Hartford area.

[Learn More >>](#)

Led by Dr. Jonathan Sporn, Chief of Hematology/Oncology, Saint Francis has 13 medical oncologists that will continue to provide cancer care through our partnership on their campus at 114 Woodland Street in Hartford.



**Syed Fazl Ali Bilgrami, MBBS** - specializes in leukemia, lymphoma, multiple myeloma; bone marrow transplant; myelodysplastic syndromes.

from the desk of

**Thomas J. Lynch, Jr., MD**

Director, Yale Cancer Center

Physician-in-Chief Smilow Cancer

Hospital at Yale-New Haven



### Recent News

Read recent articles featuring experts from Yale Cancer Center [News Center >>](#)

### LATEST ARTICLES:



The First Five Years: Smilow Cancer Hospital at Yale-New Haven [Read More >>](#)



**Robert D. Bona, MD** - specializes in lymphoma, myeloma, anemia, disorders of blood clotting.



**Adam M. Boruchov, MD** - specializes in leukemia, lymphoma, multiple myeloma, and bone marrow transplant; myelodysplastic syndromes.



**Alessia Donadio, MD** - specializes in kidney, bladder, prostate, breast and gynecologic cancers.



**Richard Edwards, MD** - specializes in lymphoma, myeloma, anemia, disorders of blood clotting.

**HARTFORD BUSINESS.com**  
A PUBLICATION OF THE HARTFORD BUSINESS JOURNAL

Yale, St. Francis team up for Hartford oncology effort

[Read More >>](#)



Smilow Cancer Hospital at Yale-New Haven and Saint Francis Care announce the launch of new partnership in Hartford

[Read More >>](#)



Encouraging Healthy Lifestyles in Breast Cancer Patients

[Read More >>](#)

**Join Yale Cancer Center on Facebook**

Like us on Facebook

**LATEST POSTS:**



**Sudhanshu B. Mulay, MD** - specializes in leukemia, lymphoma, myeloma, anemia, disorders of blood clotting.



**Susan N. Rabinowe, MD** - specializes in breast and gynecological cancers, lymphoma.



**Zia U. Rahman, MD** - specializes in breast and gynecologic cancers.



**Joerg Rathmann, MD** - specializes in lung and head and neck cancers.

New research from Yale Cancer Center links obesity, lipids, and multiple myeloma, a cancer of the plasma cells in bone marrow. Dr. Madhav Dhodapkar and his research team have found that "the host response to the lipids sets the stage for the mutations leading to multiple myeloma." Understanding the origins of multiple myeloma points the way toward new therapies and drug targets that could prevent or treat the disease.



[Learn More >>](#)

Happy Father's Day! Father's Day is especially special for one North Branford grandfather and business owner who twice has battled cancer and won.

Bill Van Wilgen, owner of Van Wilgen's Garden Center on Valley Road, will spend Sunday enjoying his first Father's Day with his 8-month-old granddaughter Nora. Now through June 28, plastic pink flamingos are for sale at [Van Wilgen's Garden Center](#) for \$10 each, with the entire amount from each sale going to Smilow Cancer Hospital.



[Read More >>](#)

Yale Cancer Center hosted an ASCO Review today for physicians to learn the latest information presented at #ASCO15 earlier this month, and information on clinical



**Carolyn Ray, MD** - specializes in breast, gynecologic, lung, colon, pancreatic cancer.



**Jonathan R. Sporn, MD** - specializes in melanoma; sarcoma; cancers of the gastrointestinal system: esophagus, stomach, colon, liver, pancreas, rectum, anus.



**Jaykumar R. Thumar, MD, MBBS** - specializes in application of Proteomics for biomarker discovery in breast cancer, melanoma, and colon cancer. Androgen receptor biology in prostate cancer.



**James J. Vredenburgh, MD** - specializes in neuro-oncology including primary brain tumors, brain metastases and carcinomatous meningitis.

trials at Smilow Cancer Hospital. Over 175 clinicians from around the Northeast joined us for a day of presentations, networking, and collaboration.



[Read More >>](#)

A recent study in the New England Journal of Medicine from Yale Cancer Center revealed that by removing an extra layer of tissue during a lumpectomy, the number of times women had to undergo a second surgery for breast cancer was reduced by 50%. Watch the WTNH News 8 story to learn more.



[Read More >>](#)

It's hard to believe that 5 years have gone by since the first patients were cared for at Smilow Cancer Hospital. Over those 5 years, many amazing stories of hope and inspiration, and incredible breakthroughs have been celebrated. Share your stories, and take a moment to watch The First Five Years from Smilow.



## Funding and Award Opportunities

### Gabrielle's Angel Foundation for Cancer Research Medical Grants

To support the conduct of innovative and insightful medical research on hematologic malignancies. Funds are provided for clinical or basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies for patients with leukemia, lymphoma, and related cancers of the blood.

**Internal Deadline:** June 29, 2015

[Learn More >>](#)

### Lung Cancer Research Foundation Grants

One-year grants of up to \$75,000 will be awarded to projects focused on basic science, translational research, clinical research, supportive care, and/or quality of care/outcomes.

**Application Deadline:** July 1, 2015

[Learn More >>](#)

### Yale Cancer Center Discovery Fund Grants

To support exceptionally innovative or unconventional collaborative cancer research at Yale Cancer Center with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies.


In order for Yale Cancer Center to reach its potential as one of the nation's top cancer centers, it has to conduct research with the potential to transform our understanding of the causes of cancer or to revolutionize our ability to study, prevent, treat, or cure cancer. Such research is intrinsically high-risk and is unlikely to fare well in review in the current conservative NIH funding environment. In addition, such research will often require the assembly of collaborative multidisciplinary teams that bring different perspectives to a complex problem. To stimulate collaborative high-impact cancer research, the YCC is establishing the Yale Discovery Fund grant program. These grants will provide relatively long-term, generous support to allow teams of investigators to embark on ground-breaking, innovative high-risk/high-reward cancer research. These grants will be supported by the venture philanthropy model, in which they will be funded primarily by substantial gifts from a limited number of donors who will play an active role in the selection of successful applications and will be regularly reviewed of progress. Our goal is that the


[Read More >>](#)


### Follow Yale Cancer Center on Twitter


Follow us on  [twitter](#)


#### LATEST TWEETS:


 Exciting to see many milestones in the last decade. We're working hard to continue to fill the timeline w/ advances!


 @DrRoyHerbstYale declared, "YES! #Nivolumab is the new standard of care for previously treated non-squamous NSCLC." <http://bit.ly/1CrqeMT>

 New research from Dr. Madhav Dhodapkar @YaleCancer links #obesity, lipids, & multiple myeloma.

 Bored of your gym workout? Enjoy the outdoors & ride. Challenge yourself to ride #ClosertoFree @CTFRide. Register at <http://bit.ly/1K6Jo2l>

 #FathersDay is especially special for a CT man who has battled #Cancer twice & won. Read how Bill is giving back

 A well-written critical read on #clinicaltrials <http://nyti.ms/1BsO7IA> @nytimes @ynhh @YaleMed #cancerresearch #Cancer

 Dr. Pat LoRusso: advanced molecular profiling for every #cancer patient will become the norm. We must work smarter with basic scientists.

research supported by these grants will be transformative: it will create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. In addition, we hope that teams not selected for funding will continue to meet and collaborate and refine their proposals for submission to other internal and external grant competitions.

**Letter of Intent Deadline:** July 8, 2015

[Learn More >>](#)

### **NCCN Pfizer Metastatic Breast Cancer Request for Proposals**

National Comprehensive Cancer Network® (NCCN®) is pleased to announce it is collaborating with Pfizer's Independent Grants for Learning & Change (IGLC) team to offer a grant opportunity focused on improving care for patients with metastatic breast cancer, where treatment goals focus on improving quality and length of life as there is, to date, no known cure.

**Letter of Intent Deadline:** July 15, 2015

[Learn More >>](#)

### **AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway**

The AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway represents a joint effort to encourage and support a physician-scientist to conduct cancer research on the HER Family Pathway and to establish a successful career path in this field. Eligibility is limited to junior faculty-level physician-scientists who, at the start of the grant term, will have completed their most recent medical residency or doctoral degree within the past 11 years.

**Application Deadline:** July 22, 2015

[Learn More >>](#)

### **Faculty Scholars Competition**

The Simons Foundation, Howard Hughes Medical Institute (HHMI) and the Bill & Melinda Gates Foundation are pleased to announce the Faculty Scholars Competition, a national competition for grants to outstanding early-career scientists.

The three philanthropies will award a total of \$148 million over the program's first five years, awarding up to 70 grants every two and a half to three years. The awards are intended for basic researchers and physician scientists who have already demonstrated significant research

 Not quite 30,000 people but a packed room for our post-#asco15 CME event

## **Closer to Free**

# **closer to free**

The fund to advance cancer research and enhance patient care

## **Events**

**June 28; 6:00 PM**

**Yale Cancer Center Answers  
WNPR**

Targeted Therapy for Lung Cancer  
Scott Gettinger, MD

[Read More >>](#)

**June 21; 6:00 PM**

**Yale Cancer Center Answers  
WNPR**

Hematopoiesis  
Joao Pereira, PhD

[Read More >>](#)

**July 15; 10:00 AM**

**YCC Cancer Prevention and  
Control Retreat on Catchment**

BCMM 206/208

Cancer Research and Outreach in  
our Community of New Haven and  
Connecticut

[Read More >>](#)

## **Submissions**

Please submit your recent  
publication and grant  
announcements to:

**Renee Gaudette**

Director, Public Affairs and  
Marketing

[renee.gaudette@yale.edu](mailto:renee.gaudette@yale.edu)

accomplishments and show potential to make unique and important contributions to their fields.

The Faculty Scholars Competition marks the first time that HHMI, the Bill & Melinda Gates Foundation and the Simons Foundation have formally undertaken an initiative together.

**Application Deadline:** July 28, 2015

[Learn More >>](#)

### **AACR NextGen Grants for Transformative Cancer Research**

These three-year grants of \$450,000 represent a new AACR funding initiative to stimulate highly innovative research from young investigators. Eligibility is limited to junior faculty who have held a full-time, tenure-track appointment as an assistant professor for no more than three years.

**Letter of Intent Deadline:** August 10, 2015

[Learn More >>](#)

### **Patterson Trust Fellowship Program in Clinical Research**

The Robert E. Leet and Clara Guthrie Patterson Trust was established in 1980 for the advancement of medical science, particularly research "relating to human diseases, their causes and relief." Two-year fellowships of \$90,000 (\$45,000 per year) will be awarded to Applicants working in Connecticut or New Jersey.

The Patterson Trust will provide support to early-stage mentored investigators conducting clinical research with a focus on patient-oriented or translational laboratory research. The Program will help the Trust to pursue its mission by providing Applicants with the opportunity to demonstrate creativity and explore opportunities that may promote careers in clinical research. Pilot and preliminary studies are encouraged.

**Application Deadline:** August 14, 2015

[Learn More >>](#)

### **Provocative Questions in Cancer with an Underlying HIV Infection (R01)**

The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant



to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.

**Application Deadline:** August 18, 2015

[Learn More >>](#)

#### **Class of '61 Yale Cancer Research Award**

In order to recognize significant accomplishment and continuing outstanding promise in cancer research, Yale Cancer Center is pleased to announce the Class of '61 Yale Cancer Research Award. This annual award recognizes significant accomplishment in cancer research at Yale University by a young member of the faculty, coupled with the expectation for future outstanding contributions to our understanding of the causes and cures for cancer. The annual award, established through the ongoing generosity of the Yale College Class of 1961, will provide unrestricted funds to support the winner's cancer research. The initial award will be \$50,000. Nominees must be Yale faculty members age 45 or less, whose accomplishments are documented by published papers and awarded grants in any area of cancer research including seminal investigations into basic cancer biology, important translational or clinical studies, or critical population science studies.

**Nomination Deadline:** August 31, 2015

[Learn More >>](#)

#### **Assay Validation For High Quality Markers For NCI-Supported Clinical Trials**

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. In addition, analytical validation of assays for these markers should be achieved when the application is submitted so that clinical validation may be achieved with little further analytical validation needed. This supplement may be used to support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among



scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

**Application Deadline:** October 7, 2015

[Learn More >>](#)

### **Smoking Cessation within the Context of Lung Cancer Screening**

The goal of this Funding Opportunity Announcement (FOA) is to improve the effectiveness and/or implementation of smoking cessation interventions delivered to current smokers who undergo low-dose computed tomography (LDCT) lung cancer screening. The proposed projects must be aimed at determining:

- a) the key components and characteristics of an effective smoking cessation intervention delivered in the LDCT setting; and/or
- b) characteristics of an implementation strategy to optimally incorporate existing evidence-based smoking cessation intervention(s) into the LDCT setting.

**Application Deadline:** October 8, 2015

[Learn More >>](#)

## **Recent Publications**

### **E2F8 as a Novel Therapeutic Target for Lung Cancer.**

Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS.

J Natl Cancer Inst. 2015 Jun 18;107(9).

[Read More >>](#)

### **Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.**

Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB.

J Clin Oncol. 2015 Jun 22.

[Read More >>](#)

### **Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.**

Iyer SP, Foss FF.

Oncologist. 2015 Jun 22.

[Read More >>](#)

**Variation in Surgical Margins Status by Surgical Approach Among Patients Undergoing Partial Nephrectomy for Small Renal Masses.**

Tabayoyong W, Abouassaly R, Kiechle JE, Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC, Zhu H, Ialacci S, Kim SP.

J Urol. 2015 Jun 18. pii: S0022-5347(15)04211-1.

[Read More >>](#)

**Gastric cancer associated variant of DNA polymerase beta (Leu22Pro) promotes DNA replication associated double strand breaks.**

Rozacky J, Nemec AA, Sweasy JB, Kidane D.

Oncotarget. 2015 Jun 10.

[Read More >>](#)

**Small-Molecule-Mediated Degradation of the Androgen Receptor Through Hydrophobic Tagging.**

Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD, Crews CM.

Angew Chem Int Ed Engl. 2015 Jun 17.

[Read More >>](#)

**Pilot Trial of Selecting Molecularly-Guided Therapy for Patients with non-V600 BRAF Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.**

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Jun 10.

[Read More >>](#)

**The effect of pre-existing mental health comorbidities on the stage at diagnosis and timeliness of care of solid tumor malignances in a Veterans Affairs (VA) medical center.**

Wadia RJ, Yao X, Deng Y, Li J, Maron S, Connery D, Gunduz-Bruce H, Rose MG.

Cancer Med. 2015 Jun 9.

[Read More >>](#)

**Complications and mortality following surgery for oral cavity cancer: Analysis of 408 cases.**

Schwam ZG, Sosa JA, Roman S, Judson BL.

Laryngoscope. 2015 Jun 9.

[Read More >>](#)

**Clostridium Perfringens Enterotoxin C-terminal domain labeled to fluorescent Dyes for in vivo visualization of micro-metastatic chemotherapy-resistant ovarian cancer.**

Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Int J Cancer. 2015 Jun 9.

[Read More >>](#)

**Risk Reduction from Weight Management and Physical Activity Interventions.**

Irwin ML, Fabian C, McTiernan A.

Adv Exp Med Biol. 2015;862:193-212.

[Read More >>](#)